Arcutis Biotherapeutics (ARQT) Liabilities and Shareholders Equity (2019 - 2026)

Arcutis Biotherapeutics' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $460.0 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 33.68% year-over-year to $460.0 million; the TTM figure through Mar 2026 stood at $1.6 billion (up 2.62% YoY), while the FY2025 annual figure was $433.0 million, up 24.1% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $460.0 million, up from $433.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $508.9 million in Q3 2022, with the low at $293.0 million in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $371.0 million (2025), against an average of $389.8 million.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity sank 42.43% in 2023, then surged 49.29% in 2024.
• Arcutis Biotherapeutics' Liabilities and Shareholders Equity stood at $449.3 million in 2022, then declined by 24.02% to $341.4 million in 2023, then rose by 2.2% to $348.9 million in 2024, then gained by 24.1% to $433.0 million in 2025, then gained by 6.24% to $460.0 million in 2026.
• Business Quant data shows ARQT's Liabilities and Shareholders Equity at $460.0 million in Q1 2026, $433.0 million in Q4 2025, and $371.0 million in Q3 2025.